AbD Serotec of Martinsried, Germany, and e2v biosensors of Chelmsford, UK, have launched a research program to perform feasibility studies showing proof of concept of the British company’s Visucare biosensor system. The system, a detection technology for biomarkers that uses a single-antibody immunoassay, will be used for protein quantification in point-of-care and near-patient testing.